Benjamin R. Puliafito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Benjamin R. Puliafito has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Diana Cirstea
Hematology and Oncology Division, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
4 shared publications - Andrew Jenho Yee
Mass General Brigham Cancer Institute, Boston, USA
3 shared publications - Andrew Robert Branagan
Massachusetts General Hospital, Boston, Massachusetts, United States
3 shared publications - Marcela V. Maus
Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States
3 shared publications - Mark B. Leick
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts
3 shared publications - Matthew J. Frigault
Massachusetts General Hospital 3 Boston, MA
3 shared publications
Latest Publications
- 19 October 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) affect most patients receiving axicabtagene ciloleucel (axi-cel) for relapsed or refractory large B-cell lymphoma (LBCL). Based on pre-clinical data, we hypothesized that prophylactic IFN-γ blockade could prevent toxicity without impairing efficacy. We initiated an open-label phase 2 trial (NCT06550141) evaluating single-dose emapalumab one day before axi-cel. Here, we report the first two patients to caution against the pre-emptive emapalumab use prior axi-cel: Both developed treatment-refractory toxicities including high-grade ICANS and overlapping CRS-IEC-HS requiring multiple immunomodulatory agents. CAR T-cell expansion exceeded levels reported in ZUMA-1 and a standard-of-care axi-cel cohort at our institution. Despite therapeutic emapalumab and suppressed free IFN-γ, IL-2 and sIL-2R were markedly elevated, suggesting CRS was driven independent of IFN-γ. Both patients achieved complete responses, suggesting preserved efficacy. Given the unanticipated severity and refractoriness of toxicities, recruitment with this design was discontinued and the protocol was amended.
- 19 October 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) affect most patients receiving axicabtagene ciloleucel (axi-cel) for relapsed or refractory large B-cell lymphoma (LBCL). Based on pre-clinical data, we hypothesized that prophylactic IFN-γ blockade could prevent toxicity without impairing efficacy. We initiated an open-label phase 2 trial (NCT06550141) evaluating single-dose emapalumab one day before axi-cel. Here, we report the first two patients to caution against the pre-emptive emapalumab use prior axi-cel: Both developed treatment-refractory toxicities including high-grade ICANS and overlapping CRS-IEC-HS requiring multiple immunomodulatory agents. CAR T-cell expansion exceeded levels reported in ZUMA-1 and a standard-of-care axi-cel cohort at our institution. Despite therapeutic emapalumab and suppressed free IFN-γ, IL-2 and sIL-2R were markedly elevated, suggesting CRS was driven independent of IFN-γ. Both patients achieved complete responses, suggesting preserved efficacy. Given the unanticipated severity and refractoriness of toxicities, recruitment with this design was discontinued and the protocol was amended.
- Top Cited Papers
- 7 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147  (19) , 2215-2225
Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea
Intractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma with reported mortality rates of 36% to 50%. The optimal clinical management is unknown. Here, we report a series of 5 patients who presented with severe diarrhea after BCMA CAR T-cell treatment. We hypothesized that the Janus kinase inhibitor, ruxolitinib, might be an effective therapy based on its success in graft-versus-host-disease after allogeneic bone marrow transplant and other immune-driven diarrhea syndromes. Three patients received ruxolitinib, all of whom experienced rapid clinical improvement. Among the 2 patients with matched pretreatment and posttreatment biopsies, both showed signs of histopathologic response, including 1 with CAR T-cell–associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract.
- 7 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147  (19) , 2215-2225
Top Cited PapersRuxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea
Intractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma with reported mortality rates of 36% to 50%. The optimal clinical management is unknown. Here, we report a series of 5 patients who presented with severe diarrhea after BCMA CAR T-cell treatment. We hypothesized that the Janus kinase inhibitor, ruxolitinib, might be an effective therapy based on its success in graft-versus-host-disease after allogeneic bone marrow transplant and other immune-driven diarrhea syndromes. Three patients received ruxolitinib, all of whom experienced rapid clinical improvement. Among the 2 patients with matched pretreatment and posttreatment biopsies, both showed signs of histopathologic response, including 1 with CAR T-cell–associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract.
- Open Access
- 17 October 2025
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 1  (3)
Impact of body mass index on anti-BCMA chimeric antigen receptor T-cell therapy outcomes in multiple myeloma
- 17 October 2025
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 1  (3)
Open AccessImpact of body mass index on anti-BCMA chimeric antigen receptor T-cell therapy outcomes in multiple myeloma
- Top Cited PapersOpen Access
- 16 September 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9  (18) , 4720-4726
Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels
Bispecific antibodies (bsAbs), such as teclistamab, elranatamab, linvoseltamab, and talquetamab, have impressive efficacy in multiple myeloma (MM) but come with substantial infectious risks that do not dissipate over time. Immunoglobulin replacement therapy (IgRT), which includes IV and subcutaneous (SC) immunoglobulins, may lower these risks. In this viewpoint, we contrast primary IgRT prophylaxis (initiation regardless of IgG levels) with preemptive IgRT treatment (initiation only once IgG levels fall below a certain threshold) in this setting. We make evidence-based arguments for primary prophylaxis as a safer and simpler approach than preemptive IgG-guided IgRT. We also discuss strategies to improve the cost-effectiveness of IV and SC immunoglobulins across the world. Given the overwhelmingly favorable benefit-risk profile of IgRT, coupled with the limitations inherent to IgG measurements in MM, withholding IgRT access based on arbitrary IgG thresholds is neither scientifically sound nor clinically appropriate for patients with MM who are receiving bsAb therapy.
- 16 September 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9  (18) , 4720-4726
Top Cited PapersOpen AccessImmunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels
Bispecific antibodies (bsAbs), such as teclistamab, elranatamab, linvoseltamab, and talquetamab, have impressive efficacy in multiple myeloma (MM) but come with substantial infectious risks that do not dissipate over time. Immunoglobulin replacement therapy (IgRT), which includes IV and subcutaneous (SC) immunoglobulins, may lower these risks. In this viewpoint, we contrast primary IgRT prophylaxis (initiation regardless of IgG levels) with preemptive IgRT treatment (initiation only once IgG levels fall below a certain threshold) in this setting. We make evidence-based arguments for primary prophylaxis as a safer and simpler approach than preemptive IgG-guided IgRT. We also discuss strategies to improve the cost-effectiveness of IV and SC immunoglobulins across the world. Given the overwhelmingly favorable benefit-risk profile of IgRT, coupled with the limitations inherent to IgG measurements in MM, withholding IgRT access based on arbitrary IgG thresholds is neither scientifically sound nor clinically appropriate for patients with MM who are receiving bsAb therapy.
- Top Cited Papers
- 5 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145  (23) , 2788-2793
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
Potentially fatal non-immune effector cell–associated neurotoxicity syndrome neurotoxicities (NINTs) after B-cell maturation antigen–targeted chimeric antigen receptor (CAR) T-cell therapy have been linked to high CAR T-cell expansion. Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory NINTs.
- 5 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145  (23) , 2788-2793
Top Cited PapersCyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
Potentially fatal non-immune effector cell–associated neurotoxicity syndrome neurotoxicities (NINTs) after B-cell maturation antigen–targeted chimeric antigen receptor (CAR) T-cell therapy have been linked to high CAR T-cell expansion. Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory NINTs.
- 22 June 2022
- Published by BMJ in BMJ Case Reports
- Vol. 15  (6) , e249637
Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma
Although patients with multiple myeloma (MM) have improved survival with current therapies, there remains a long-term risk of treatment-associated second primary malignancies. We present a case of a patient with IgG kappa MM undergoing treatment for relapsed disease who was noted to have progressive pancytopenia. For his MM, he had previously undergone autologous stem cell transplant with high-dose melphalan and had received immunomodulatory (IMiD) agents in induction, maintenance and relapse regimens. A peripheral blood smear showed abnormal lymphoid cells, and a bone marrow biopsy revealed B-cell acute lymphoblastic leukaemia (B-ALL). He underwent intensive induction chemotherapy with plans for possible allogeneic stem cell transplant. Secondary B-ALL is a rare occurrence in patients with MM, with exposure to alkylating and IMiD agents being potential risk factors.
- 22 June 2022
- Published by BMJ in BMJ Case Reports
- Vol. 15  (6) , e249637
Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma
Although patients with multiple myeloma (MM) have improved survival with current therapies, there remains a long-term risk of treatment-associated second primary malignancies. We present a case of a patient with IgG kappa MM undergoing treatment for relapsed disease who was noted to have progressive pancytopenia. For his MM, he had previously undergone autologous stem cell transplant with high-dose melphalan and had received immunomodulatory (IMiD) agents in induction, maintenance and relapse regimens. A peripheral blood smear showed abnormal lymphoid cells, and a bone marrow biopsy revealed B-cell acute lymphoblastic leukaemia (B-ALL). He underwent intensive induction chemotherapy with plans for possible allogeneic stem cell transplant. Secondary B-ALL is a rare occurrence in patients with MM, with exposure to alkylating and IMiD agents being potential risk factors.
- 1 March 2021
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56  (7) , 1717-1719
Comparison of post-transplant vaccination among allogeneic and autologous hematopoietic stem cell transplant patients: a single center quality analysis
- 1 March 2021
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56  (7) , 1717-1719
Comparison of post-transplant vaccination among allogeneic and autologous hematopoietic stem cell transplant patients: a single center quality analysis